InSite Vision Incorporated is an ophthalmic product development company focused on ophthalmic pharmaceutical products based on its DuraSite drug delivery technology. Its DuraSite sustained delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a variety of potential drug candidates. It focused its research and development and commercial efforts on topical anti-infective products that formulate the antibiotic azithromycin with its DuraSite drug delivery technology. Its primary products include AzaSite for Bacterial Conjunctivitis (pink eye); AzaSite Plus (ISV-502), which is in Phase III Trials for Blepharoconjunctivitis; AzaSite Otic (ISV-016) a pre-clinical development for ear infections, and AzaSite Xtra (ISV-405) a pre-clinical development for Ocular Infections in International Markets.
(Source: 10-K)
